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This review discusses the metabolism of arachidonic acid to
prostaglandins (PG) and other metabolites and the site of
physiological action of these products along the nephron.
Potential pathophysiological contributions of renal PG will be
briefly reviewed. The breakdown of prostaglandins will not be
discussed and the reader is referred to several excellent articles
on the subject [1, 2].
General principles of prostaglandin synthesis
The biosynthetic pathway leading to the formation of the
unstable intermediate endoperoxides from arachidonic acid
(AA) seems to be identical in all tissues investigated [1].
Subsequent conversion of the endoperoxides follows a tissue-
specific pattern resulting in the formation of different PG by
different tissues. The endoperoxides are synthesized by a single
enzyme which is a glycoprotein with two enzymatic sites,
cyclooxygenase and hydroperoxidase [II. The endoperoxides
can then be transformed by prostacyclin-synthase to PGI2, by
thromboxane synthase to TXA2, by PG isomerases to PGE2 and
PGD2, and by endoperoxide reductase to yield PGF2,. (Fig. 1).
There is, in addition, also some nonenzymatic decomposition
of PGH2 into PGE2 and PGD2 [1]. It remains unclear at this
point whether the reduction from PGH2 to PGF2,. is an enzy-
matic reaction. Most crude homogenates contain enough thiol
compounds and hemoproteins to generate significant amounts
of PGF2. by nonenzymatic reduction from PGH2 [1].
The different enzymes involved in the formation of the
various PUs have specific cofactor requirements (Table 1) so
that the pattern of PG production can change depending on the
preparation and conditions used and need not at all reflect the
pattern of PG formation in intact tissue. For example, the
relationship of the different PGs produced by kidney
microsomes can be altered depending on the addition of various
cofactors [21. Also, the pattern of PG formed may vary with the
enzyme/substrate ratio and substrate concentration [2]. Finally,
the ratio of cyclooxygenase to isomerase may be different in
various tissues so that different results will be obtained depend-
ing on whether AA or PGH2 are used as substrate (for example,
see [3D.
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Control of PG-synthesis
Cyclooxygenase activity. Changes in cell cyclooxygenase
activity (half-life 24 hr) may occur slowly under certain condi-
tions and can chronically change the capacity for PG synthesis.
Such alterations in total cyclooxygenase activity have been
observed, for example, in rats with congenital diabetes
insipidus after chronic administration of antidiuretic hormone
[4]. A different mechanism may underlie the increase in cyclo-
oxygenase after unilateral ureteral ligation [5—8] or renal venous
obstruction [91. In these instances it appears that the increase in
enzyme does not occur in the renal cells, themselves, but is
instead due to proliferation of inflammatory cells [10].
Substrate availability. Under normal physiological conditions the
amount of free intracellular AA, that is available for cyclooxygenase
is negligible [1]. Apart from the activity of cyclooxygenase in a given
tissue, the major factor controlling PG-synthesis is the availability of
free AA. AA is esterified in the 2 position of the phospholipid,
predominantly in phosphatidylinositol but also in phosphatidyleho-
line and phosphatidylethanolamine.
Most likely both phospholipase C and phospholipase A2
activation are involved in the release of AA [11—12]. Agreement
exists that the enzymatic steps leading to the release of AA are
calcium-dependent [1]. Phospholipase A2 in the renal medulla
[12—14] may be a calcium-calmodulin-dependent enzyme, while
phospholipase C appears to be calmodulin-independent [15, 161.
In the isolated kidney [17] and kidney slices [7] and cultured
mesangial cells [181, there are specific pools of AA linked to
cyclooxygenase activity, while other AA pools are unrelated to
PG-synthesis. Furthermore, metabolism of only a small per-
centage of the AA pool in phospholipids seems to be hormone
responsive [7, 181.
The amount of membrane-bound AA converted to cyclooxy-
genase or lipoxygenase products is only a small fraction of the
total. Only a few percent of the cellular AA is released even
after maximal hormone stimulation, and of this, only a fraction
(10 to 40%) is transformed by cyclooxygenase, while the rest
may be reincorporated into phospholipids [17]. The fact that the
hormone responsive AA pool is small compared to the total
phospholipid-bound AA complicates studies which rely on the
prelabeling of phospholipids with exogenous AA, because
under most conditions the total phospholipid pool is labeled
nonspecifically [7]. Prelabeling of the specific hormone respon-
sive pool may be facilitated by prior hormone stimulation [19].
Further complicating matters, different individual phospholip-
ids also have different turnover rates and are represented to
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Fig. 1. Scheme of biologically active compounds derived from arachidonic acid. (Reprinted from [II with permission)
differing degrees within the cells. For example, phosphatidyl-
inositol only represent 5 to 10%, while phosphatidylcholine and
phosphatidylethanolamine each account for about 30% of the
total phospholipids. Thus, small changes in the turnover of
phosphatidyicholine and phosphatidylethanolamine may re-
lease as much AA as much more marked changes in phosphati-
dylinositol turnover. For all these reasons, the exact source of
AA and the mechanism of its release have yet to be defined
fully.
Inhibition of phospholipase. An endogenous inhibitor of
phospholipase has been described in neutrophils [20—22] and
renal medulla [22]. This inhibitor is a protein that is synthetized
and released in response to glucocorticoids. It has been called
macrocortin [20], lipomodulin [21], orrenocortin [22]. Lipomod-
ulin has been shown to inhibit both phospholipase A2 and C in
vitro [21].
Other factors influencing AA availability. In addition to
release of AA by phospholipase, factors that influence the AA
availability include:
(1) Binding of AA to protein. AA avidly binds to both extra
and intracellular proteins and as such is no longer available for
cyclooxygenase. Thus, not all intracellular AA is "free" and
can be utilized for PG synthesis [1].
(2) Reincorporation of AA. AA released from the
phospholipids may be reincorporated rapidly into phospholipids
[1, 17]. This reaction competes with cyclooxygenase for AA [7,
18]. As the reincorporation into phospholipids requires ATP,
the reaction may be slowed during hypoxia, which, in turn,
could lead to higher concentrations of nonesterified AA. This
Table 1. Some characteristics of enzymes involved in prostaglandin
synthesis
Formation of Location Cofactors
Cyclo-AA
oxygenase PGG2
.Hemin
Particulate
Hydro-PGG2 .peroxluase PGH2 Aromatic compounds (forexample, tryptophan)
as reducing substrate
PGE2 Particulate Glutathione
PGI2 Particulate None known
Thromboxane Particulate None known
PGD2 Soluble
albumin (?)
Glutathione (?)
PGF2 Enzymatic (?) Thiol compounds and
hemoproteins
may be one explanation for increased PG synthesis observed
during hypoxia [23—25].
(3) Competition forAA. In addition to cyclooxygenase, AA is
also a substrate for lipoxygenase and epoxygenase. This com-
petition for free AA could influence PG-synthesis. Further-
more, the products of these enzymes may in turn influence
phospholipases and the cyclooxygenase system. These path-
ways are only beginning to be explored in the kidney.
Lipoxygenase products and the kidney
Formation of lipoxygenase products by the kidney. Arachi-
donic acid can also be metabolized via lipoxygenase pathways
0
PGG2 OOH
[H)
6-keto-PGF1
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(Figs. 1 and 2) [26]. To our knowledge, the formation of small
amounts of 12-HETE by guinea pig kidney homogenates was
first demonstrated by Hamberg [27]. Recently, Winokur and
Morrison [28] demonstrated formation of 12-HETE and 15-
HETE (identified by gas chromatography followed by mass
spectrometry) by a cytosolic preparation from rabbit renal
medulla but not from the cortex. The lipoxygenase activity was
increased in hydronephrotic kidneys, a finding similar to the
increase in cyclooxygenase activity in hydronephrotic kidneys
[5]. In the hydronephrotic kidney, it remains unclear whether
these products are truly of renal cell origin or are produced by
invading inflammatory cells [10]. The enzyme required calcium
and was inhibited by the lipoxygenase inhibitors eicosatetray-
noic acid (ETYA) and phenidone, but not by indomethacin [28].
Lipoxygenase products have been identified lately by gas
chromatography-mass spectrometry as 12-HETE in rat
glomeruli [29, 301 and as 12- and 15-HETE in human glomeruli
[30].
It is to be expected that lipoxygenase products will be
identified in other renal structures, as more attention is directed
toward these products and as analytical detection methods are
improving. The physiological significance of these lipoxygenase
products in renal function remains to be determined but is
certain to attract much interest in the near future. Lately, it has
been postulated that lipoxygenase products may play a role in
experimental immune injury to the glomerulus [31—33].
Metabolism of leukotrienes in the kidney. To date no evi-
dence exists for 5-HETE formation and subsequent leukotriene
production by kidney tissue (Fig. 2). Systemic infusion of
leukotrienes, however, does influence renal function [34]. It is
therefore reasonable to assume that leukotrienes released from
inflammatory cells within the kidneys may influence renal
hemodynamics and capillary permeability, as they do in other
systems [261. Also, the kidney may be involved in the metabo-
lism of leukotrienes. Transformation of LTC3 to the biologically
more active LTD3 by gamma-glutamyltranspeptidase has been
demonstrated in the kidney [35]. Conversion of LTD to LTE
has also been demonstrated in the porcine kidney [36] and is
associated with a tenfold decrease in biological activity. In vivo
the kidney may play a role in the metabolism and inactivation of
leukotrienes as suggested by total body autoradiography of
mice after injection of [3H]-labeled leukotriene C3 [37].
Epoxygenase pathway
In addition to cyclooxygenase and lipoxygenase, the kidney
contains mixed function oxidases that are involved in the
metabolism of fatty acids and also PG [38—41]. Recently, it has
been shown that AA can be converted by NADPH-dependent,
cytochrome P-450 to oxidation products (Fig. 3); [42—44]. They
include dihydroxyeicosatrienoic acids oxidized at the 5,6; the
8,9; the 11, 12 and the 14,15 position as well as 19,20-
hydroxyeicosatetraenoic acids, 19-oxoeicosatetraenoic acid,
and eicosatetraen-l,20-dioic acid. The formation of these prod-
ucts by renal cortical microsomes depended on the pesence of
NADPH which cannot be substituted for NADH. 02 is also
necessary for their formation [42—44]. The formation of the 11,
12- and the 14,15-dihydroxyeicosatetraenoic acid occurred
probably via the intermediate epoxides 11(12)- and 14(15)-
oxido-cis-5,8,14 eicosatrienoic acid. The dihydroxyacids can be
metabolized further to trihydroxy acids [44] (Fig. 3). It is
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Fig. 2. Formation of leukotrienes via the 5-lipoxygenase pathway.
GGTP is y-glutamyl transpeptidase. (Reprinted from [26] with
permission)
possible that a cytochrome P-450-linked epoxygenase system is
involved in the formation of metabolites that previously were
mistaken for cyclooxygenase or lipoxygenase products.
An intriguing finding is the production of considerable
amounts of AA derivatives by the thick ascending loop of Henle
that derive from neither cyclo- nor lipoxygenase pathways and
may be epoxygenase products [45—47]. The epoxygenase path-
way is certain to attract considerable interest, especially as 5,6
epoxyeicosatrienoic acid, a product of a renal NADPH-depen-
dent monooxygenase pathway, can inhibit sodium transport in
isolated collecting tubules [48] and vasopressin's hydroosmotic
action in the toad urinary bladder [49].
PG-synthesis in the kidney
The kidney, and especially the renal medulla, is one of the
most active PG-producing tissues. Homogenates or micro-
somes from the entire kidney produce PGE2, PGF2, 6 keto
PGF1,, TXB2, and PGD2 to varying degrees depending on the
conditions used [2]. The isolated perfused kidney produces
predominantly PGE2 [5, 50] but also can release PG!2 [51], and
under certain circumstances, TXB2 [52, 531. Table 2 lists factors
influencing renal PG synthesis.
There are marked regional differences in the quantity and
pattern of PG production within the kidney. As PGs are locally
active agents, the pattern of PGs produced by different nephron
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Table 2. Factors stimulating PG synthesis by the kidney in vivo or
perfused in vitro
Stimulating factor Reference
Angiotensin II 7, 17, 23, 54—56
Bradykinin 7, 17, 23, 55, 58—60
Vasopressin 61—63
Catecholamines and renal nerve
stimulation 50, 60, 64
Converting enzyme inhibitor 65
Mannitol 66
Renal perfusion rate 67—69
segments is important. PG synthesis increases from cortex to
medulla [701 and has been examined recently in isolated
glomeruli, different tubular segments, interstitial cells, or cells
derived from various nephron segments.
Localization of prostaglandin synthase by histochemical or
immunofluorescence methods. Localization of prostaglandin
synthase activity within the kidney has been performed by
histochemical staining for peroxidase activity [71, 72] and
indirect immunofluorescence for cyclooxygenase [73]. Both
methods have yielded remarkably similar results. In the renal
cortex of rabbit, cow, rat, sheep, and guinea pig, positive
immunofluorescence for cyclooxygenase was observed in the
endothelial cells of arteries and arterioles but not in the capil-
laries or venous tree [73]. Glomerular epithelial cells of
Bowman's capsule stained positive in the rabbit only, whereas
in bovine and ovine glomeruli, the fluorescence was present in
a mesangial distribution. Proximal tubules, the loop of Henle,
and distal convoluted tubules, including the macula densa, were
negative by both immunofluorescence and peroxidase methods
[71, 72]. It should be considered, however, that the im-
munofluorescence staining for cyclooxygenase activity gives
only a qualitative picture and a negative staining reaction does
not rule out cyclooxygenase activity but could just indicate
levels below the detection limit.
In the renal medulla both histochemical and immunofluores-
cence methods show strongly positive staining in collecting
tubule cells and interstitial cells [71—73].
PG-synthesis by different nephron segments. (1) Renal cor-
tex. To better characterize the source of PG synthesis in renal
cortical tissue, isolated nephron segments have been examined
for PG synthesis. PG!2 synthesis has been shown to be promi-
nent in microdissected cortical arteries and arterioles [74]. Rat
glomeruli produce mainly PGE2 and PGF2,, and less PGI2 and
TXB2 [75—78]. Human glomeruli synthesize mainly PGI2 (deter-
mined as 6 keto PGF1a,) and also some TXB2, PGE2 and PGF2a
[79, 80].
Localization of PG synthesis within the glomerulus has been
studied using primary cultures of glomerular cells. Rat cultured
mesangial cells synthesize almost exclusively PGE2 [80, 811
while mesangial cells from humans produce predominantly
PGI2, [82] similar to the isolated human glomerulus [83]. Rat
glomerular epithelial cell cultures seem to have the same profile
as mesangial cells but the amount of PGs produced may be
smaller [80, 84]. Kreisberg, Karnovsky, and Levine [85] have,
however, reported considerable and predominant synthesis of 6
keto-PGF1, by epithelial cells in culture. The problem of
actually identifying the cultured cells to be of glomerular
visceral epithelial origin makes it difficult to assign an exact PG
profile to the epithelial cells.
In contrast to isolated glomeruli, cortical tubules, consisting
of predominantly proximal tubules, produce very little PG
[76—78, 86] consistent with the absence of either peroxidase
/
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Fig. 3. Tentative pathway of arachidonic acid metabolism leading to trihydroxy metabolites in fortfled rabbit kidney microsomes by the
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years. The literature is extensive and shall not be reviewed in
detail. Several excellent reviews dealing with the physiological
and pathophysiological aspects of renal prostaglandins have
16, 77 appeared. The reader is referred to them for a more extensive
76, 80, 87 treatment [I 15—I 17].
At present there is convincing evidence that prostaglandins
89 influence: (1) renal blood flow and glomerular filtration, (2) the
90 release of renin, and (3) the urinary concentrating mechanism.
18 82 A contribution of prostaglandins to NaCI and perhaps phos-
18' 82 83 92 93 phate and hydrogen ion handling by the kidney—independent of
82, 83
' ' blood flow—is likely, but not fully established. Finally, a role of
83, 94 prostaglandins in the control of renal erythropoeitin production
has been postulated.
PG and the control of renal blood flow and glomerular
95 filtration. In general the importance of renal prostaglandins for
84 the inaintenancc of blood flow and glomerular filtration can be
95 demonstrated only under conditions where the vasoconstrictor
—
system is activated [118—119]. Similar to the vasculature in
other organs PGE2 and PGI2 are vasodilators in the kidney
medullary tissue
___________________________ ________________________ [120]. Occasional vasoconstriction observed after PGE2 or PGI2
administration may be secondary to an increase in renin release
14 47 106 107 and consequently angiotensin II formation [1211. When the
14, 105, io formation of angiotensin II is blocked, both PGE2 and PG!2 act
II, 107, 109, 1 io as renal vasodilators. On the other hand, thromboxane is a
110 potent vasoconstrictor that also contracts isolated glomeruli' [122]. The physiological role of the vasodilatorprostaglandins is
14, 110, 112 most likely to counteract the effect of vasoconstrictors. Renal
vasoconstrictors increase synthesis of vasodilatatory prosta-
los glandins (see Tables 2 to 4) and thus act as a negative feedback.
86, 105 Prostaglandins may affect renal blood flow to varying degrees
105 in different regions of the kidney [123, 124]. Inhibition of
102, 103 endogenous prostaglandin synthesis will preferentially decrease
101, 103 medullary blood flow, possibly indicating that the high renal
medullary PG synthesis maintains blood flow to this poorly
98,113 oxygenated and hypertonic region of the kidney.
98 Prostaglandins also play a contributory role in renal autoreg-
98, 114 ulation [125]. As modulators of renal vascular tone and mesan-
gial contraction, prostaglandins also influence glomerular filtra-
tion rate (GFR) [117, 121, 122, 125]. They may do so by
changing the afferent and efferent arteriolar resistance [121,
125], by influencing the renin-angiotensin system [117, 121,
125], and finally, by directly affecting the glomerular filtration
characteristics via changes in mesangial contraction [122]. The
glomerulus can decrease its size in response to various vasoac-
tive agents [122, 126], presumably by mesangial cell contraction
[82, 83, 94, 126—1281. This contraction is attenuated by concom-
itant increases in the synthesis of vasodilatory PGs [94, 122],
Thus, locally produced prostaglandins may also directly influ-
ence the effective glomerular filtration surface. Micropuncture
experiments have demonstrated that prostaglandins may also
contribute to tubuloglomerular feedback regulation [125]. In-
deed, the local production of renin, angiotensin II and
prostaglandin and their respective interactions would be suited
ideally for regulation of individual glomerular function.
The role of intrarenal prostaglandins in the maintenance of
renal blood flow and GFR is even more evident in various renal
diseases. PG synthesis may contribute to maintain renal func-
tion in patients with systemic lupus erythematosus, congestive
heart failure, chronic renal failure, liver cirrhosis, diabetes
mellitus, volume depletion, diuretics, or old age. (For a corn-
Tissue
Table 3. Factors stimulating PG synthesis in glomeruli
Stimulating factor Reference
Isolated glorneruli
Cultured glomerular
mesangial cells
Cultured glomerular
epithelial cells
A23 187
Angiotensin 11
Converting enzyme
inhibitor
Hydrogen peroxide
Mercury chloride
A23 187
Angiotensin 11
Vasopressin
Platelet activating factor
Bradykinin
Zymosan
A23 187
Angiotensin II
Vasopressin
Table 4. Factor stimulating PG synthesis in renal
Tissue Stimulating factor Reference
Medullary slices and
medullary cell
suspensions
Isolated collecting
tubules
Cultured collecting
tubule cells
Cultured renomedullary
interstitial cells
A 23187
Vasopressin
Angiotensin II
Bradykinin
Furosemide
Hypertonic medium
(NaCI, mannitolj
A 23187
Vasopressin
Bradykinin
Vasopressin
Bradykinin
Angiotensin II
Vasopressin
Bradykinin
Hypertonic medium
stain or immunofluorescence for cyclooxygense in this tubular
segment. Table 3 summarizes factors known to influence PG
synthesis in isolated glomeruli and cultured glomerular cells.
(2) Renal medulla. In agreement with the histochemical and
immunofluorescent studies, the major sources of PGE2 produc-
tion within the medulla are collecting tubules and interstitial
cells. Both rabbit interstitial cells in culture [96—99] and isolated
or cultured [100—103] collecting tubule cells very actively pro-
duce PG, predominantly PGE2, and to a lesser extent, PGF2.
and PG!2. In addition the same pattern of prostaglandin synthe-
sis is observed in microdissected collecting tubules [86, 104,
105]. Other elements of the renal medulla, for example, the loop
of Henle, exhibit very little PG production [47, 104]. The
thick-ascending loop of Henle may, however, have consider-
able epoxygenase activity [45, 46]. Table 4 indicates agents that
alter PG synthesis in collecting tubules and medullary intersti-
tial cells.
Physiological and pathophysiological considerations
The physiological role of prostaglandins in modifying various
renal functions has become increasingly apparent over the last
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plete review of the effects of PG-synthesis inhibitors on renal
function refer to [129, 130].) The possibility that imbalances
between vasodilatory PG and the vasoconstrictor thromboxane
play a role in renal diseases has also been raised based on
results with experimental unilateral ureteral obstruction [5, 6,
131], acute renal failure [52, 91, 132], renal transplant rejection
[133], and experimental nephrotoxic serum nephritis [134].
Changes in intraglomerular hemodynamics can significantly
influence the filtration, deposition, and subsequent handling of
macromolecules (for example, proteins and immune com-
plexes) by the glomerulus [135]. Thus, vasoactive agents could
hfluence glomerular immune-injury; this process could, in turn,
be modulated by intraglomerular production of PGs [94].
PG and the control of renin release. PGs, particularly PGE2
and PGI2, have been demonstrated to enhance plasma renin
activity in vivo and directly increase renin release in vitro and
thus represent one of the multiple factors controlling renin (for
review, see [1361).
In vitro studies showed that locally produced PGs act on
renin secretion by renal cortical preparations [1361. Stimulation
of renin release also occurs in isolated glomeruli superfused
with arachidonic acid PGE2 or PG!2 [137], and this is blocked by
PG synthesis inhibition. The mechanism of action of PGs on
renin release seems to involve cyclic AMP as second messenger
[138] and both PGE2 and PGI2 stimulate cyclic AMP generation
in rat [139] and human glomeruli [140].
PG in the urinary concentrating mechanism. Ever since the
original observation that PGE1 inhibits the effect of antidiuretic
hormone in the toad urinary bladder [1411 and in the mammalian
collecting tubule [142], the interaction of ADH with PG has
attracted much interest. Multiple studies have confirmed that
PGE1 and PGE2 antagonize the antidiuretic action of ADH both
in vitro and in vivo. [143—1451.
Two major questions that have attracted considerable inter-
est are: (1) How does PG interfere with the renal concentrating
mechanism? (2) Does ADH directly enhance the synthesis of
prostaglandins in its target organ closing a negative feedback
loop?
Concerning the first question, several possible mechanisms
exist. PG could interfere with the renal concentrating mecha-
nism by increasing renal medullary blood flow leading to the
washout of solute and dissipation of the osmotic gradient
required for water reabsorption. PG may also influence medul-
lary solute composition by decreasing sodium transport and
urea accumulation in the medulla. Both of these effects could be
independent of ADH. Consistent with this formulation, medul-
lary NaCI concentration increases after inhibition of PG syn-
thesis and decreases after administration of PGE2 [146, 147].
Thus, PG could influence medullary solute composition and
hence urinary concentrating ability even in the absence of ADH
[148]. Also, urea permeability of the toad urinary bladder [149]
and the mammalian collecting tubule [150] increases after
inhibition of PG synthesis while exogenous PG decreases urea
permeability. It has been shown that vasopressin stimulates
adenylate cyclase and enhances NaCI reabsorption via cyclic
AMP in the medullary thick ascending limb of Henle. More-
over, two laboratories independently have shown that PGE2
inhibits adenylate cyclase and NaCI reabsorption in this neph-
ron segment in a dose-dependent manner in response to vaso-
pressin [151, 152]. Since NaCI reabsorption in this nephron
segment is central to the generation and maintenance of the
medullary hypertonicity, these data suggest that PGE2 can also
affect the urinary concentration mechanism by modifying the
action of vasopressin in the thick ascending limb of Henle's
loop.
The major effect of PG in the concentrating mechanism is its
interference with the cellular mechanism of action of ADH.
Studies in the toad urinary bladder [153, 154] in segments of the
thick ascending loop of Henle and in isolated collecting tubules
[151, 152, 155, 1561, and in vivo [157] have shown that PGE2
interferes with the ADH-induced cyclic AMP generation prob-
ably via an inhibitory subunit of the adenylate cyclase. While
this effect can be shown in intact tissue, an inhibitory action of
PG on ADH-stimulated adenylate cyclase in broken cell prep-
arations has not been uniformly found [1581. Furthermore,
PGE2 at concentrations of 10-6 M and upward may even
increase cellular cyclic AMP concentrations [14, 153, 1541.
Therefore, the possibility of an additional inhibitory action of
PG at a site distal to the generation of cyclic AMP has been
postulated [154]. Finally, it has been proposed that thrombox-
ane may directly enhance vasopressin's action [159] though
these findings remain controversial [160].
The second question, that is, whether ADH directly enhances
the synthesis of prostaglandins in its target organ thereby
closing a negative feedback loop as originally proposed by
Zusman, Keiser, and Handler [161], has resulted in some
seemingly contradictory answers. In the toad urinary bladder
stimulation of PGE2 and thromboxane synthesis after ADH has
been reported [159, 161]. Other groups were unable to detect a
significant effect of ADH on PGE2 synthesis in the toad bladder
or toad bladder epithelial cells [162—164]. At present it appears
that the reason for the differences may in part relate to
differences in the preparation of the tissue [165, 166].
In studies with mammalian tissue, interstitial cells in culture,
medullary slices and cell suspensions, collecting tubule cells in
culture, and microdissected collecting tubules have been used.
In medullary slices and cell suspensions ADH usually stimu-
lates PGE2 synthesis to some extent (see Table 4). These
preparations do, however, contain both interstitial and collect-
ing tubule cells, and thus, do not allow one to attribute the
increase in PGE2 synthesis to a specific cell. In primary cultures
of medullary collecting tubule cells ADH increased cyclic AMP
concentration but did not stimulate PGE2 synthesis [101]. On
the other hand, in cultures of cortical collecting tubules ADH
increased PGE2 synthesis [102, 103]. Similarly, ADH and DD
AVP were found to increase PGE synthesis in isolated cortical
collecting tubules [86]. Studies carried out in our laboratory
indicate that some of the differences may be due to the in vitro
incubation conditions and that, under certain conditions, ADH
can increase PGE2 synthesis in both cortical and medullary
collecting tubules [105].
A number of points have to be considered to explain these
discrepant results. For example, PGE2 synthesis by toad uri-
nary bladder, medullary slices, and isolated collecting tubules
decreases progressively with incubation time [14, 105, 163]. The
absence of a stable baseline makes it difficult to unequivocably
demonstrate stimulation, unless this occurs to a very marked
degree. Demonstration of ADH-induced PGE2 synthesis may
be complicated further by the fact that cyclic AMP can decrease
PG production probably by inhibiting phospholipase activity.
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Based on the observation that 8 bromo cyclic AMP can inhibit
PGE2 synthesis in renal medullary cells and toad bladder
epithelial cells under basal and ADH-stimulated conditions, it
has been proposed recently that ADH and PGE2 may interact in
a dual feedback loop [1661. In this scheme ADH would increase
PGE2 synthesis by activating phospholipases in a cyclic AMP-
independent manner as originally proposed by Zusman, Keiser,
and Handler [161]. The resulting increase ofPGE2 will, in turn,
inhibit ADH's hydroosmotic effect, to a large extent by inter-
fering with cyclic AMP generation. On the other hand, the
increase in cyclic AMP could inhibit phospholipase activation
and the resulting synthesis of PGE2, representing a second
feedback loop that would tend to prevent an overshoot of both
the ADH and PGE2 effect in either direction.
Contribution of PG to renal NaC1 excretion. Despite a
considerable amount of experimental data from both in vivo and
in vitro studies, the evidence for a blood-flow independent role
for prostaglandins in renal NaCI excretion remains controver-
sial. In vivo, depending on the experimental conditions (for
example, prior NaCI content of diet, volume status, water
diuresis, or antidiuresis, awake or anesthesia, and so forth),
intrarenal administration of PGE or inhibition of renal PG
production has provided results that indicate: (1) renal PG do
not influence renal NaCI excretion; (2) PG inhibit NaCI excre-
tion, or (3) PG increase renal NaCI excretion [115, 116, 1671.
These conflicting results are not overly surprising as the phys-
iological status of the animal can alter the effect of prostaglan-
dins on renal blood flow and its distribution. Though some
studies attempt to minimize or exclude changes in blood flow, it
remains doubtful whether this factor can ever be eliminated
adequately during in vivo studies. Studies using urinary PGE2
excretion as an index of renal PG synthesis have occasionally,
but not always, shown a correlation between urinary PG and
NaCI excretion.
Studies using the isolated perfused tubule have resulted
similarly in conflicting results [1671. While several groups have
shown inhibition of NaCI transport by PGE2 or PGI2 in the
cortical collecting tubule [168—1 70] or the thick ascending loop
of Henle [171] from rabbits, another group has been unable to
show such an effect [172, 173]. The reason for these discrepan-
cies remains unclear and cannot be explained easily by differ-
ences in hormonal status, basal NaCI transport, or buffers used.
If PGE2 produced by the collecting tubule inhibits NaCl trans-
port, it remains unclear why inhibition of collecting tubular PG
synthesis does not result in enhancement of NaCI transport.
Holt and Lechene [1741 did, however, report that PG-inhibition
prevented the vasopressin-induced changes in Na-transport in
cortical collecting tubules. Studies using simultaneous measure-
ments of NaCI transport and PGE2 synthesis by isolated col-
lecting tubules might be helpful in resolving the role of PGE2 in
NaCI transport by this segment. Also, it is possible that
noncyclooxygenase products of arachidonic acid influence
NaCI transport. For example, PGE2 has been postulated to
inhibit NaCl transport in the thick ascending limb of Henle's
loop [171]. The thick ascending loop of Henle, however,
produces only very small amounts of prostaglandins [104, 122,
125]. On the other hand, cells from this segment seem to have
a high capacity to metabolize arachidonic acid to noncycloox-
ygenase products possibly via the epoxygenase pathway [45,
661. The possibility that such products influence NaCI transport
has been reported [48] and will have to be examined further.
Conceivably, the effect of PGE2 on NaCI transport observed in
isolated tubules may be an indirect one secondary to an
influence of the added PGE2 on the formation of
noncyclooxygenase products.
Role of PG in renal phosphate excretion. Published reports
on the effects of PGs on renal phosphate transport are also
conflicting. Beck et al [175] showed that PGE1 alone was mildly
antiphosphaturic but that it markedly inhibited the phosphaturic
response to PTH in intact dogs. In contrast, Strandhoy et al
[1761 reported that PGE1 increased the fractional excretion of
phosphate in intact dogs whereas PGE2 was inactive. In further
studies Fragola et al [177] confirmed that PGE2 by itself had no
effect on phosphate excretion in thyroparathyroidectomized
dogs, but abolished the phosphaturic action of PTH in vivo.
This effect occurred only if PGE2 infusion preceded the admin-
istration of PTH. More recently, the same group using the
microperfusion technique showed a dual role for PGE2. PGE2,
like PTH, inhibited phosphate transport in the proximal straight
segment of the rabbit nephron, but also antagonized the effect
of PTH [178]. Taken together, these results could suggest that
the interaction of PTH and PGE in vivo could represent tubular
desensitization to PTH by PGE2.
In rabbit cortical collecting tubules, Holt and Lechene [174]
demonstrated that ADH inhibited calcium and phosphorus
reabsorption and that pretreatment with meclofenamate
blocked this effect of ADH whereas PGE2 mimicked the effect.
From these studies, the authors concluded that phosphate
reabsorption in the cortical collecting tubule may be decreased
by PGE2 synthesized in response to ADH.
In summary some evidence supports a role for PG to inhibit
tubular phosphate transport. It should be recalled however, that
the proximal tubule, the major site of phosphate transport, has
very little capacity to produce PG [76, 77, 86]. Also to date, no
unequivocal effect of PG inhibition on proximal tubular phos-
phate transport has been demonstrated.
Role of PG in renal erythropoeitin production. A role for
renal PG in the production and release of erythropoeitin by the
kidney has been postulated based on some indirect experimen-
tal evidence [179, 180]. Unfortunately, our knowledge of the
synthesis of erythropoeitin by the kidney and its control is too
scanty at this point to allow a critical evaluation of this issue.
Role of prostaglandins in various renal diseases
Because of the multiple contributions of prostaglandins to
various renal functions, it is not surprising that abnormal
prostaglandin synthesis has been invoked to contribute to a
variety of disease states. In cases of threatened renal function,
the enhanced PG synthesis may help to maintain renal blood
flow and glomerular filtration (see Renal blood flow above). The
possible role of prostaglandins in systemic hypertension of
various etiologies continues to attract considerable interest.
Changes in renal PG synthesis have been described in several
models of hypertension, Again, it remains unclear whether the
changes in PG synthesis represent a primary contributing factor
or a secondary reaction [1811.
Surprisingly, a possible contributory role of inhibition of
prostaglandin synthesis to the etiology of analgesic nephrop-
athy has not been investigated extensively. Nonsteroidal
antiinflammatory drugs, all of which are PG-synthesis inhibi-
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